Medical Device Nonvisual Accessibility Act of 2025

The Medical Device Nonvisual Accessibility Act of 2025 (HR5605) was introduced in the House on September 26, 2025, and subsequently referred to the House Committee on Energy and Commerce. This bill aims to amend the Federal Food, Drug, and Cosmetic Act to establish nonvisual accessibility standards for certain medical devices equipped with digital interfaces. The bill is currently in an early stage of the legislative process, having only been introduced and referred to committee. This legislation does not contain explicit funding authorizations or appropriations. Instead, it mandates new regulatory requirements for medical device manufacturers. Companies will incur development costs to ensure compliance with nonvisual accessibility standards. However, the bill also identifies an expanded addressable market by enabling blind and low-vision individuals to independently and safely use medical devices. The mechanism of impact is regulatory, requiring manufacturers to adapt product design rather than direct government spending or grants. Structural winners include technology companies that develop screen access technology or other nonvisual interface solutions, such as Microsoft ($MSFT) and Alphabet ($GOOGL), as their expertise will be in demand for integration into medical devices. Medical device manufacturers like Medtronic plc ($MDT), Intuitive Surgical, Inc. ($ISRG), Abbott Laboratories ($ABT), Tandem Diabetes Care, Inc. ($TNDM), and DexCom, Inc. ($DXCM) are positioned to face initial compliance costs but could benefit from increased market penetration among blind and low-vision consumers if they successfully integrate these features. The bill states that devices can be designed with nonvisual access technology at little or no extra cost if considered early in the design process. Recent market data shows varied performance among medical device companies. Medtronic plc ($MDT) is at $86.28, down 7.24% over 30 days but up 0.63% over 7 days. Intuitive Surgical, Inc. ($ISRG) is at $452.58, down 8.88% over 30 days and down 0.04% over 7 days. Abbott Laboratories ($ABT) is at $102.3, down 7.87% over 30 days but up 0.41% over 7 days. Tandem Diabetes Care, Inc. ($TNDM) is at $19.17, down 15.29% over 30 days and down 2.09% over 7 days. DexCom, Inc. ($DXCM) is at $63.21, down 10.58% over 30 days but up 2.12% over 7 days. Technology companies Microsoft ($MSFT) and Alphabet ($GOOGL) are at $372.88 and $299.99 respectively, with Microsoft down 9.2% over 30 days and up 3.88% over 7 days, and Alphabet down 0.3% over 30 days and up 9.69% over 7 days. The current market trends for these companies do not directly reflect the impact of this specific bill, given its early legislative stage. For HR5605 to become law, it must pass through the Committee on Energy and Commerce, then be voted on by the full House, pass the Senate, and be signed by the President. As of today, 2026-04-07, the bill remains in the initial committee review phase. The presence of 17 cosponsors, including bipartisan support from both Democrats and Republicans, indicates some level of legislative interest, but passage is not guaranteed.